Epigenetic therapy for ovarian cancer: promise and progress

Sara Moufarrij,
Monica Dandapani,
Elisa Arthofer,
Stephanie Gomez,
Aneil Srivastava,
Micael Lopez-Acevedo,
Alejandro Villagra and
Katherine B. ChiappinelliEmail author

Clinical Epigenetics201911:7

https://doi.org/10.1186/s13148-018-0602-0

Received: 11 October 2018
Accepted: 19 December 2018
Published: 15 January 2019

Abstract

Ovarian cancer is the deadliest gynecologic malignancy, with a 5-year survival rate of approximately 47%, a number that has remained constant over the past two decades. Early diagnosis improves survival, but unfortunately only 15% of ovarian cancers are diagnosed at an early or localized stage. Most ovarian cancers are epithelial in origin and treatment prioritizes surgery and cytoreduction followed by cytotoxic platinum and taxane chemotherapy. While most tumors will initially respond to this treatment, recurrence is likely to occur within a median of 16 months for patients who present with advanced stage disease. New treatment options separate from traditional chemotherapy that take advantage of advances in understanding of the pathophysiology of ovarian cancer are needed to improve outcomes. Recent work has shown that mutations in genes encoding epigenetic regulators are mutated in ovarian cancer, driving tumorigenesis and resistance to treatment. Several of these epigenetic modifiers have emerged as promising drug targets for ovarian cancer therapy. In this article, we delineate epigenetic abnormalities in ovarian cancer, discuss key scientific advances using epigenetic therapies in preclinical ovarian cancer models, and review ongoing clinical trials utilizing epigenetic therapies in ovarian cancer.